Gilder Gagnon Howe & CO LLC Allogene Therapeutics, Inc. Transaction History

Gilder Gagnon Howe & CO LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$7.65 - $15.29 $221 - $443	-29 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$25.79 - $39.02 $309 - $468	-12 Reduced 29.27%	29 $1,000
Q4 2020 Feb 16, 2021	SELL	$25.24 - $43.45 $1.56 Million - $2.68 Million	-61,775 Reduced 99.93%	41 $1,000
Q3 2020 Nov 16, 2020	SELL	$32.38 - $44.96 $3.2 Million - $4.44 Million	-98,704 Reduced 61.49%	61,816 $2.33 Million
Q2 2020 Aug 14, 2020	BUY	$18.39 - $54.04 $2.95 Million - $8.67 Million	160,520 New	160,520 $6.87 Million
Q1 2020 May 15, 2020	SELL	$18.22 - $28.25 $39,756 - $61,641	-2,182 Closed	0 $0
Q1 2019 May 17, 2019	SELL	$24.82 - $32.54 $1,017 - $1,334	-41 Reduced 1.84%	2,182 $63,000
Q4 2018 Feb 14, 2019	BUY	$22.5 - $33.3 $50,017 - $74,025	2,223 New	2,223 $60,000

165

134M

59.4K

113K

Ticker ALLO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 143,807,008
Market Cap $279M
Description
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...

Get notified when there are updates to the investment portfolio of Gilder Gagnon Howe & CO LLC, based on Form 13F filings with the SEC.

Stay updated on Gilder Gagnon Howe & CO LLC with notifications on news.